Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer

Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015

(2015) A. S. Coates et al.   ANNALS OF ONCOLOGY

Clinical utility of genetic signatures in selecting adjuvant treatment: Risk stratification for early vs. late recurrences

(2015) Daniel F. Hayes   BREAST

Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

(2015) M. Dowsett et al.   CLINICAL CANCER RESEARCH

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

(2015)   LANCET

Clinicopathological characteristics of breast cancer and trends in the management of breast cancer patients in Japan: Based on the Breast Cancer Registry of the Japanese Breast Cancer Society between 2004 and 2011

(2015) Junichi Kurebayashi et al.   Breast Cancer

Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer

(2014) Mitsuchika Hosoda et al.   BREAST CANCER RESEARCH AND TREATMENT

Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer

(2013) Ben P. Haynes et al.   BREAST CANCER RESEARCH AND TREATMENT

Menopausal Status Should Be Taken Into Consideration for Patients With Luminal A Breast Cancer in Terms of the Effect of Differential Biology on Prognosis

(2013) Yutaka Yamamoto et al.   JOURNAL OF CLINICAL ONCOLOGY

Factors Predicting Late Recurrence for Estrogen Receptor–Positive Breast Cancer

(2013) Ivana Sestak et al.   JNCI-Journal of the National Cancer Institute

Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials

(2013)   LANCET

Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population

(2013) Dennis C Sgroi et al.   LANCET ONCOLOGY

EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer

(2012) P. Dubsky et al.   ANNALS OF ONCOLOGY

Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial

(2012) Christina Davies et al.   LANCET

Genetic and environmental predictors, endogenous hormones and growth factors, and risk of estrogen receptor-positive breast cancer in Japanese women

(2011) Nobuyasu Yoshimoto et al.   CANCER SCIENCE

Breast Cancer Adjuvant Therapy: Time to Consider Its Time-Dependent Effects

(2011) Ismail Jatoi et al.   JOURNAL OF CLINICAL ONCOLOGY

The 2011 EBCTCG polychemotherapy overview

(2011) Carlo Palmieri et al.   LANCET

Estrogen receptor-positive breast cancer in Japanese women: trends in incidence, characteristics, and prognosis

(2010) H. Yamashita et al.   ANNALS OF ONCOLOGY

Relationship Between Plasma Estradiol Levels and Estrogen-Responsive Gene Expression in Estrogen Receptor–Positive Breast Cancer in Postmenopausal Women

(2010) Anita K. Dunbier et al.   JOURNAL OF CLINICAL ONCOLOGY

Qualitative Age Interactions in Breast Cancer Studies: Mind the Gap

(2009) William F. Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen

(2008) Hagen Kennecke et al.   CANCER

Late Extended Adjuvant Treatment With Letrozole Improves Outcome in Women With Early-Stage Breast Cancer Who Complete 5 Years of Tamoxifen

(2008) Paul E. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY